HC Wainwright Issues Pessimistic Outlook for EPRX Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Eupraxia Pharmaceuticals in a report released on Thursday, May 14th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.25) per share for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at ($0.79) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01).

A number of other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. William Blair started coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They set an “outperform” rating for the company. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ:EPRX opened at $6.69 on Tuesday. The company’s 50-day moving average is $7.26 and its 200 day moving average is $7.31. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The company has a market capitalization of $404.28 million, a P/E ratio of -6.37 and a beta of 1.19. Eupraxia Pharmaceuticals has a fifty-two week low of $3.67 and a fifty-two week high of $9.32.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in EPRX. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals during the third quarter valued at about $71,000. Bank of America Corp DE lifted its holdings in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. Guardian Wealth Advisors LLC NC purchased a new stake in Eupraxia Pharmaceuticals during the fourth quarter valued at about $76,000. Aptus Capital Advisors LLC purchased a new stake in Eupraxia Pharmaceuticals during the fourth quarter valued at about $76,000. Finally, Geode Capital Management LLC purchased a new stake in Eupraxia Pharmaceuticals during the fourth quarter valued at about $105,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.